Truist Securities Maintains Buy on Inspire Medical Systems, Lowers Price Target to $217
Portfolio Pulse from Benzinga Newsdesk
Truist Securities maintains a Buy rating on Inspire Medical Systems (NYSE:INSP) but lowers the price target from $280 to $217.
July 16, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Inspire Medical Systems but lowers the price target from $280 to $217.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100